Precision BioSciences (DTIL) announced that it has received clinical trial application, or CTA, approval in Moldova for its lead candidate, PBGENE-HBV. PBGENE-HBV is Precision’s wholly owned in vivo gene editing program designed to cure chronic hepatitis B by eliminating cccDNA, the key source of replicating hepatitis B virus, while also inactivating integrated HBV DNA in hepatocytes. The company has opened the Phase 1 clinical program and is moving towards dosing patients.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DTIL:
- Precision BioSciences submits CTA to start trial for PBGENE -HBV
- Three new option listings and eighteen option delistings on September 23rd
- Precision BioSciences Reshuffles Clinical Leadership Team
- Precision BioSciences chief medical officer Alan List to retire
- Precision BioSciences Secures Funds, Bolsters Oncology Partnership